Retiro De Equipo (Recall) de Nellix EndoVascular Aneurysm Sealing System

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por AA-Med Pty Ltd.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
  • ID del evento
  • Clase de Riesgo del Evento
    Class I
  • Fecha de inicio del evento
  • País del evento
  • Fuente del evento
  • URL de la fuente del evento
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    The pre-market clinical trials & post-market surveillance data showed that the rates for device migration, endoleak, and/or aneurysm enlargement were higher than anticipated. a root cause investigation, including consultation with physicians and review of ct scans of patients with the events was completed. based upon this, endologix is updating the instructions for use (ifu) with more detailed information regarding the indications for use, patient selection criteria & procedural best practices.Furthermore, patients exhibiting the following key anatomic elements may be at risk regardless of the nellix system version being implanted: · anatomies outside of the respective, specific criteria defined as part of the indications for use · narrow aortoiliac bifurcation not suitable for balloon-expandable stent deployment· formation of thrombus &/or calcium at the arterial implantation sites, specifically the proximal aortic neck and distal iliac artery interface (i.E., sealing zone).
  • Acción
    The outcome of the investigation resulted in the refined indication for use, patient selection criteria, and procedural best practices as outlined in the customer letter. Endologix representative will provide additional training on the key IFU changes to enable Physicians and their team to become familiar with the updated IFU prior to formal availability. Physicians are notified that all patients should be advised that endovascular treatment requires life-long, regular follow-up to assess their health and the performance of their endovascular implant. Patients with specific clinical findings (e.g., endoleaks, enlarging aneurysms or changes in the structure or position of the endovascular implant) should receive enhanced follow-up. Additional endovascular intervention or conversion to standard open surgical repair should be considered for patients continuing to experience enlarging aneurysms, implant displacement, and/or significant endoleaks during post-operative follow up. This action has been closed-out on 17/05/2017.


  • Modelo / Serial
    Nellix EndoVascular Aneurysm Sealing SystemARTG Numbers: 234418 , 235301, 271832, 271833
  • Manufacturer


  • Source